Our study has identified the first genotype-specific enhanced effect of XPO1 inhibition with mechanistic support for the combination of eltanexor and venetoclax as a promising targeted strategy for therapy for SF3B1-mutant MDS and AML, addressing a significant lack of approved therapies targeting spliceosomal mutations. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.